last two paragraphs reproduced here;
4. Bartram and Hodkinson not treated with HiQCell
While it was not expressly mentioned in the story, the way it was compiled may have left the viewer
under the impression that HiQCell was the reason for former AFL player Clint Bartram’s treatment
failure. Regeneus notes that Mr Bartram was not treated using HiQCell.
The story also reports that current NRL player Trent Hodkinson was treated with a stem cell injection by
Regeneus. This is incorrect, as Mr Hodkinson was not treated with HiQCell or by any other Regeneus
procedure.
5. The story inferred that Regeneus had taken shortcuts in the evaluation of safety and efficacy.
HiQCell has been used to treat over 550 patients in Australia since 2011. This includes patients in a
world-first double blind clinical study (OSCARS), and commercial patients, many of whom are followed
in an ethics approved HiQCell Joint Registry. This dataset shows that the treatment is effective in
reducing pain in 73% of follow-up patients at one year and 82% of follow up patients at 2 years posttreatment,
as well as reducing reliance on medication and improving quality of life. The success rate of
HiQCell is published on the HiQCell website (http://hiqcell.com.au/about-hiqcell/patient-results/) and
communicated to patients by HiQCell licensed medical specialists.
RGS Price at posting:
19.0¢ Sentiment: Hold Disclosure: Held
